15What Preserved Hearing Buys, and Where This Is Going

FThe payoff: electric-acoustic stimulation

Electric-acoustic stimulation (EAS, or hybrid) delivers natural acoustic amplification for the preserved low frequencies in the same ear that the implant electrically stimulates the high frequencies - one ear, two complementary signals. The acoustic component restores cues the electric signal conveys poorly: fundamental frequency, temporal fine structure and interaural timing - the cues that carry pitch, voice quality and the ability to follow one talker in noise. In the pivotal Nucleus Hybrid trial most recipients kept measurable hearing and the large majority continued to use EAS at follow-up, with speech scores improved over their pre-operative best-aided performance. The benefit is largest in exactly the situations electric-only listeners find hardest - background noise and music (cross-reference the Bilateral/Bimodal and Music modules for the listening science).[2016][2013]

TBetter in noise, better music, more natural sound

Adding preserved acoustic hearing gives a measurable speech-in-noise advantage - on the order of a couple of decibels of signal-to-noise ratio, translating to several to many percentage points of improvement in complex listening environments. Low-frequency acoustic hearing carries pitch and timbre, so music and voice sound more natural and recognisable than with electric stimulation alone. When the contralateral ear also has acoustic hearing (EAS plus a hearing aid, or bilateral low-frequency hearing), localisation and spatial release from masking improve through better access to interaural timing cues. These gains are the clinical justification for accepting the added surgical effort and risk of trying to preserve hearing rather than simply implanting a full-length array.[2013][2016]

CManaging delayed loss and the bail-out to full electric

Even with good initial preservation, some recipients lose residual hearing over months; counselling must set this expectation before surgery so the patient understands EAS may not be permanent. Strategy depends on electrode choice: a shorter hybrid array maximises preservation but, if hearing is lost, may not reach the apex - whereas a longer flexible array offers a fall-back to full electric coverage if the acoustic hearing fails. If residual hearing is lost, the acoustic component is switched off and the map is converted to full electric stimulation across the array - the 'bail-out', which is smoother when the array already spans enough cochlea. This trade-off (preservation-optimised short array vs preservation-attempt with a longer fall-back array) is a core device-selection decision, linked to the Devices and EAS material in Chapter 14.[2016][2014]

CThe operating room of the future

Robotic and motorised insertion delivers the consistently slow, low-force advancement (around 0.1 mm/s) that human hands cannot sustain, reducing intracochlear pressure and improving preservation in early matched cohorts. Real-time ECochG feedback is being coupled to these systems to move toward closed-loop, 'smart' insertion: the response from the cochlea modulates how the robot advances, automatically pausing on a drop. Drug-eluting and steroid-releasing arrays aim to blunt the inflammatory and fibrotic response that drives delayed loss, so that hearing preserved at insertion stays preserved (cross-reference the Emerging Technology chapter). The convergence of atraumatic arrays, slow robotic insertion, intraoperative monitoring and pharmacological protection points toward routine hearing preservation becoming the default expectation - and toward extending preservation thinking to standard candidates, not only EAS candidates.[2024][2022]